Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, in… Read more
Sinphar Pharmaceutical Co Ltd (1734) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.057x
Based on the latest financial reports, Sinphar Pharmaceutical Co Ltd (1734) has a cash flow conversion efficiency ratio of 0.057x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$203.24 Million) by net assets (NT$3.57 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sinphar Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Sinphar Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sinphar Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinphar Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eastern & Oriental Bhd
KLSE:3417
|
-0.010x |
|
Grupo Hotelero Santa Fe SAB
MX:HOTEL
|
0.023x |
|
Altia Oyj
F:28Q
|
0.266x |
|
AQUILA PART PROD COM
RO:AQ
|
0.061x |
|
Track & Field Co S.A
SA:TFCO4
|
0.072x |
|
Cyient DLM Limited
NSE:CYIENTDLM
|
0.012x |
|
Gongwin Biopharm Holdings Co. Ltd.
TWO:6617
|
N/A |
|
Jeju Air Co Ltd
KO:089590
|
0.211x |
Annual Cash Flow Conversion Efficiency for Sinphar Pharmaceutical Co Ltd (2003–2024)
The table below shows the annual cash flow conversion efficiency of Sinphar Pharmaceutical Co Ltd from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$3.55 Billion | NT$593.51 Million | 0.167x | +91.89% |
| 2023-12-31 | NT$3.40 Billion | NT$296.37 Million | 0.087x | -34.03% |
| 2022-12-31 | NT$3.22 Billion | NT$425.30 Million | 0.132x | +200.15% |
| 2021-12-31 | NT$3.08 Billion | NT$135.54 Million | 0.044x | -5.41% |
| 2020-12-31 | NT$3.14 Billion | NT$146.39 Million | 0.047x | +287.63% |
| 2019-12-31 | NT$3.20 Billion | NT$-79.49 Million | -0.025x | -206.85% |
| 2018-12-31 | NT$3.42 Billion | NT$79.50 Million | 0.023x | -61.69% |
| 2017-12-31 | NT$3.63 Billion | NT$219.87 Million | 0.061x | +162.99% |
| 2016-12-31 | NT$3.78 Billion | NT$87.18 Million | 0.023x | -67.46% |
| 2015-12-31 | NT$3.96 Billion | NT$280.53 Million | 0.071x | +94.44% |
| 2014-12-31 | NT$4.08 Billion | NT$148.58 Million | 0.036x | -57.16% |
| 2013-12-31 | NT$3.49 Billion | NT$297.09 Million | 0.085x | +39.12% |
| 2012-12-31 | NT$2.69 Billion | NT$164.45 Million | 0.061x | -27.91% |
| 2011-12-31 | NT$2.66 Billion | NT$225.58 Million | 0.085x | -29.94% |
| 2010-12-31 | NT$2.16 Billion | NT$261.49 Million | 0.121x | -18.26% |
| 2009-12-31 | NT$2.09 Billion | NT$309.94 Million | 0.148x | -3.04% |
| 2008-12-31 | NT$1.77 Billion | NT$271.01 Million | 0.153x | +48.45% |
| 2007-12-31 | NT$1.70 Billion | NT$174.85 Million | 0.103x | +2.74% |
| 2006-12-31 | NT$1.66 Billion | NT$166.57 Million | 0.100x | +34.84% |
| 2005-12-31 | NT$1.64 Billion | NT$122.09 Million | 0.074x | -44.09% |
| 2004-12-31 | NT$1.32 Billion | NT$174.81 Million | 0.133x | +3.62% |
| 2003-12-31 | NT$942.90 Million | NT$120.84 Million | 0.128x | -- |